|
- Sandoz - the leading name in generic and biosimilar
Sandoz is the global leader in generic and biosimilar medicines Our Purpose is to pioneer access to medicines for patients globally
- Generics - Sandoz
© 2025 Sandoz Group AG This site is intended for a global audience
- Pioneering access for patients - sandoz-com. cms. sandoz. com
2024 was a defining year for Sandoz, marked by resilience, remarkable achievements and steady progress, even in the face of challenges such as geopolitical uncertainty We surpassed USD 10 billion in net sales for the first time and delivered on our promises with a strong core EBITDA of USD 2 1 billion and a margin of 20 1%
- Careers - Sandoz
Becoming an independent listed company in October 2023 was a pivotal moment for Sandoz that started us on an exciting multi-year journey of transformation and growth Together, we are shaping the future of Sandoz
- Sandoz 2024 Business Report
%PDF-1 6 %âãÏÓ 1287 0 obj > endobj xref 1287 25 0000000016 00000 n 0000002430 00000 n 0000002632 00000 n 0000003444 00000 n 0000003559 00000 n 0000005033 00000 n 0000005603 00000 n 0000006245 00000 n 0000006335 00000 n 0000006916 00000 n 0000007550 00000 n 0000007651 00000 n 0000008303 00000 n 0000008977 00000 n 0000013257 00000 n 0000018488 00000 n 0000022501 00000 n 0000026514 00000 n
- Company Overview - Sandoz
Under the leadership of Richard Saynor, the Sandoz leadership team is responsible for overseeing the business operations of Sandoz
- About Sandoz
The Sandoz brand dates back to 1886 We can look back on a wide range of pioneering scientific breakthroughs
- Our strategy - annualreport. sandoz. com
Sandoz continues to optimize its product mix, with mid-term growth driven by a combination of increased volume in the base business and launches across generics and biosimilars
|
|
|